Thrombolytic Science International LLC
Novel clot-dissolving drug for ischemic stroke
This article was originally published in Start Up
Thrombolytic Science International LLC’s drug candidate for acute post-stroke therapy is a mutant of pro-urokinase, a natural enzyme found in humans that, like tPA, also activates plasmin. TSI’s modified protein is designed to hold its inert, pro-enzymatic form longer in the bloodstream, enabling it to retain its occlusive clot specificity at higher, therapeutic doses with reduced risk of bleeding.
You may also be interested in...
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.